rentradВестник рентгенологии и радиологииJournal of radiology and nuclear medicine0042-46762619-0478Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists10.20862/0042-4676-2015-0-6-132-141rentrad-90Research ArticleСтатьиНекоторые закономерности развития радиоиндуцированных метахронных опухолейSome patterns of development radio-induced metachronous tumorsВаженинА. В.VazheninA. V.

д. м. н., профессор, заведующий кафедрой онкологии, лучевой диагностики и лучевой терапии

MD, PhD, DSc, Professor, Head of the Department of Oncology, Radiation Diagnosis and Radiotherapy

ШаназаровН. А.ShanazarovN. A.

д. м. н., профессор кафедры онкологии

MD, PhD, DSc, Professor of the Department of Oncology

ШунькоЕ. Л.Shun’koE. L.

к. м. н., доцент кафедры хирургических болезней с курсами эндоскопии, урологии и рентгенологии

MD, PhD, Associate Professor of the Department of Surgical Diseaseswith a Courses of Endoscopy, Urology and Radiology

ГБОУ ВПО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения РФРоссияSouth Ural State Medical University, Ministry of Health of the RFRussian FederationГБОУ ВПО «Тюменский государственный медицинский университет» Министерства здравоохранения РФРоссияTyumen State Medical University, Ministry of Health of the RFRussian Federation201509032016063035Copyright © Важенин А.В., Шаназаров Н.А., Шунько Е.Л., 20162016Важенин А.В., Шаназаров Н.А., Шунько Е.Л.Vazhenin A.V., Shanazarov N.A., Shun’ko E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.russianradiology.ru/jour/article/view/90

Цель исследования – определить особенности развития метахронных опухолей и выживаемость больных первичномножественным метахронным раком после лучевой терапии первой опухоли.

Материал и методы

Материал и методы. Материалом исследования являются архивные данные Челябинского областного онкологического диспансера по лечению 232 больных, у которых после лучевой терапии первой опухоли возникли первично-множественные метахронные опухоли.

Результаты

Результаты. Средний возраст больных на момент установления диагноза первой опухоли составил 60,23 (95% ДИ 58,75–61,72) года. Временной интервал от появления первой опухоли до появления второй опухоли составил 91,81 (95% ДИ 80,57–103,05) мес. В среднем пациенты прожили 129,41 (95% ДИ 116,55–142,28) мес от момента установления диагноза первой опухоли и 37,64 (95% ДИ 31,92–43,35) мес от момента появления второй опухоли. В целом после лучевой терапии первой опухоли пациенты прожили в среднем 127,03 (95% ДИ 114,02–140,03) мес. Были выделены три подгруппы метахронных опухолей: мультицентрические множественные опухоли в одном органе – у 16,0% больных, системные опухоли и опухоли парных органов – у 15,5% больных, несистемные множественные опухоли различных органов – у 68,5% больных.

Заключение

Заключение. Для больных с мультицентрическими метахронными множественными опухолями в одном органе характерны более молодой возраст, наиболее короткий интервал времени от момента диагностики первой опухоли до появления второй опухоли и от начала лучевой терапии, а также наибольшая выживаемость от момента установления диагноза первой опухоли, от выявления второй опухоли и от начала лучевой терапии. Для лиц с несистемными множественными опухолями различных органов характерны более старший возраст, наиболее продолжительный интервал времени от момента диагностики первой опухоли до появления второй опухоли, наименьшая выживаемость.

 

 

Objective: to determine the specific features of the development of metachronous tumors and survival rates in patients with metachronous primary and multiple cancers after radiotherapy for the first tumor.Material and methods. The archival data of the Chelyabinsk Regional Oncology Dispensary on the treatment of 232 patients, in whom metachronous primary and multiple tumors occurred after radiotherapy for primary tumor, were studied.Results. The patients’ mean age at the diagnosis of the first tumor was 60.23 years (95% CI 58,75–61,72). The time from the first tumor to the second one averaged 91.81 months (95% CI 80,57–103,05). The patients survived for an average of 129.41months (95% CI 116,55–142,28) after the diagnosis of the first tumor and 37.64 months (95% CI 31,92–43,35) after the occurrence of the second tumor. Overall, the patients survived for an average of 127.03 months (95% CI 114,02–140,03) followingradiotherapy for the first tumor. According to the classification, the authors identified three metachronous tumor subgroups: multicentric multiple tumors in one organ (16.0%), systemic tumors and tumors of paired organs (15.5%), and nonsystemic multiple tumors of different organs (68.5%).Conclusion. Patients with multicentric metachronous multiple tumors in one organ are younger and have the shortest time from the diagnosis of the first tumor to the emergence of the second one and the longest survival after the diagnosis of the firsttumor, that after the detection of the second tumor and that after the initiation of radiotherapy. Patients with nonsystemic multiple tumors in different organs areolder and have the longest time from the diagnosis of the first tumor to the occurrence of the second one and the shortest survival.

первично-множественные метахронные злокачественные опухолилучевая терапияmetachronous primary and multiple malignant tumorsradiotherapyReferencesVazhenin A.V., Bekhtereva E.I., Bekhtereva S.A., Gyulov Kh.Ya. Essays primary multiplicity of malignant tumors. Chelyabinsk: Ieroglif; 2000 (in Russian).Vazhenin A.V., Bekhtereva E.I., Bekhtereva S.A., Gyulov Kh.Ya. Essays primary multiplicity of malignant tumors. Chelyabinsk: Ieroglif; 2000 (in Russian).Shun’ko E.L. Problem risk of developing primary multiple cancer following radiotherapy and chemotherapy first tumor in modern english literature (literature review). Sovremennye problemy nauki i obrazovaniya. 2014; 6. Available at: http://www.science-education.ru/120-16901 (accessed 16.04.2015) (in Russian).Shun’ko E.L. Problem risk of developing primary multiple cancer following radiotherapy and chemotherapy first tumor in modern english literature (literature review). Sovremennye problemy nauki i obrazovaniya. 2014; 6. Available at: http://www.science-education.ru/120-16901 (accessed 16.04.2015) (in Russian).Athar B.S., Paganetti H. Comparison of second cancer risk due to outoffield doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother. Oncol. 2011; 98: 87–92.Athar B.S., Paganetti H. Comparison of second cancer risk due to outoffield doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother. Oncol. 2011; 98: 87–92.Bartkowiak D., Humble N., Suhr P., Hagg J., Mair K., Polivka B. et al. Second cancer after radiotherapy, 1981–2007. Radiother. Oncol. 2012; 105: 122–6.Bartkowiak D., Humble N., Suhr P., Hagg J., Mair K., Polivka B. et al. Second cancer after radiotherapy, 1981–2007. Radiother. Oncol. 2012; 105: 122–6.Berrington de Gonzalez A., Curtis R.E., Kry S.F., Gilbert E., Lamart S., Berg Ch.D. et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12: 353–60.Berrington de Gonzalez A., Curtis R.E., Kry S.F., Gilbert E., Lamart S., Berg Ch.D. et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011; 12: 353–60.Shin D.W., Baik Y.J., Kim Y.W., Oh J.H., Chung Ki-W., Kim S.W. et al. Knowledge, attitudes, and practice on second primary cancer screening among cancer survivors: a qualitative study. Patient Educ. Counsel. 2011; 85: 74–8.Shin D.W., Baik Y.J., Kim Y.W., Oh J.H., Chung Ki-W., Kim S.W. et al. Knowledge, attitudes, and practice on second primary cancer screening among cancer survivors: a qualitative study. Patient Educ. Counsel. 2011; 85: 74–8.Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother. Oncol. 2009; 91: 4–15.Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother. Oncol. 2009; 91: 4–15.Chaturvedi A.K., Engels E.A., Gilbert E.S. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J. Natl. Cancer Inst. 2007; 99: 1634–43.Chaturvedi A.K., Engels E.A., Gilbert E.S. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J. Natl. Cancer Inst. 2007; 99: 1634–43.Lawrence T.S., Ten Haken R.K., Giaccia A. Principles of radiation oncology. In: DeVita V.T. Jr., Lawrence T.S., Rosenberg S.A. (eds). Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008.Lawrence T.S., Ten Haken R.K., Giaccia A. Principles of radiation oncology. In: DeVita V.T. Jr., Lawrence T.S., Rosenberg S.A. (eds). Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008.Fraumeni J.F. Jr, Curtis R.E., Edwards B.K., Tucker M.A. Introduction. In: Curtis R.E., Freedman D.M., Ron E. et al. (eds). New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006: 1–7.Fraumeni J.F. Jr, Curtis R.E., Edwards B.K., Tucker M.A. Introduction. In: Curtis R.E., Freedman D.M., Ron E. et al. (eds). New malignancies among cancer survivors: SEER cancer registries, 1973–2000. Bethesda, MD: National Cancer Institute; 2006: 1–7.Berrington de Gonzalez A., Curtis R., Gilbert E. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br. J. Cancer. 2010; 102: 220–6.Berrington de Gonzalez A., Curtis R., Gilbert E. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br. J. Cancer. 2010; 102: 220–6.Lonn S., Gilbert E.S., Ron E., Smith S.A., Stovall M., Curtis R.E. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. Cancer Epidemiol. Biomarkers Prev. 2010; 9: 464–74.Lonn S., Gilbert E.S., Ron E., Smith S.A., Stovall M., Curtis R.E. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. Cancer Epidemiol. Biomarkers Prev. 2010; 9: 464–74.Clarke M., Collins R., Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087–106.Clarke M., Collins R., Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087–106.Roychoudhuri R., Evans H., Robinson D., Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Brit. J. Cancer. 2004; 91: 568–72.Roychoudhuri R., Evans H., Robinson D., Moller H. Radiation-induced malignancies following radiotherapy for breast cancer. Brit. J. Cancer. 2004; 91: 568–72.Darby S.C., McGale P., Taylor C.W., Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005; 6: 557–65.Darby S.C., McGale P., Taylor C.W., Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005; 6: 557–65.Brown L.M., Chen B.E., Pfeiffer R.M. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res. Treat. 2007; 106: 439–51.Brown L.M., Chen B.E., Pfeiffer R.M. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res. Treat. 2007; 106: 439–51.Zablotska L., Neugut A. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 2003; 97: 1404–11.Zablotska L., Neugut A. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer. 2003; 97: 1404–11.Hodgson D.C., Gilbert E.S., Dores G.M. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J. Clin. Oncol. 2007; 25: 1489–9.Hodgson D.C., Gilbert E.S., Dores G.M. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J. Clin. Oncol. 2007; 25: 1489–9.Koh E.J., Tran T.H., Heydarian M. A comparison of mantle versus involvedfield radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiation. Oncol. 2007; 2: 13.Koh E.J., Tran T.H., Heydarian M. A comparison of mantle versus involvedfield radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiation. Oncol. 2007; 2: 13.20. Cardis E., Kesminienne A., Ivanov V. Risk of thyroid cancer after exposure to 131I in childhood. J. Nat. Cancer Inst. 2005; 97: 724–32.20. Cardis E., Kesminienne A., Ivanov V. Risk of thyroid cancer after exposure to 131I in childhood. J. Nat. Cancer Inst. 2005; 97: 724–32.Scott B., Cardis E., Kesminienne A. Risk of thyroid cancer after exposure to 131I in childhood. J. Nat. Cancer. Inst. 2006; 98: 561.Scott B., Cardis E., Kesminienne A. Risk of thyroid cancer after exposure to 131I in childhood. J. Nat. Cancer. Inst. 2006; 98: 561.Xu X.G., Bednarz B., Paganetti H. A review of dosimetry studies on externalbeam radiation treatment with respect to second cancer induction. Phys. Med. Biol. 2008; 53: 193–241.Xu X.G., Bednarz B., Paganetti H. A review of dosimetry studies on externalbeam radiation treatment with respect to second cancer induction. Phys. Med. Biol. 2008; 53: 193–241.Neglia J.P., Friedman D.L., Yasui Y. Second malignant neoplasms in fiveyear survivors of childhood cancer: childhood cancer survivor study. J. Natl. Cancer Inst. 2001; 93: 618–29.Neglia J.P., Friedman D.L., Yasui Y. Second malignant neoplasms in fiveyear survivors of childhood cancer: childhood cancer survivor study. J. Natl. Cancer Inst. 2001; 93: 618–29.Slinchak S.M. Multiple malignancies. Kiev: Zdorov’e; 1968 (in Russian).Slinchak S.M. Multiple malignancies. Kiev: Zdorov’e; 1968 (in Russian).

The authors declare that there are no conflicts of interest present.